Ligand's First Clean Look At Zoma Tests A Raised Profit Floor Wall Street Hasn't Matched

Ligand Pharmaceuticals heads into its third-quarter report with an unusual mismatch between what management has promised and what analysts have penciled in. After closing the Zoma royalty acquisition and calling the current stretch its most catalyst-rich period in roughly four decades, the company tightened its 2026 adjusted earnings outlook to $9.00 to $9.50 per share, lifting the floor from $8.50. Yet the full-year consensus sits at $8.79, below the new low end. Either the Street is being stubbornly cautious, or estimates simply have not caught up. The October 29 release, due before the open, should settle which.

For the quarter, analysts expect adjusted earnings of $2.26 per share on revenue of $77.1 million. The Earnings Whisper of $2.35 sits modestly above consensus, a sign that the informal bar is higher than published numbers suggest, which fits with the guidance raise. The headline revenue comparison will look ugly, with sales expected to fall about 33% from $115.5 million a year ago, when results were swollen by an outsized period that produced $5.68 in EPS. That comparison says little about the royalty engine. The more relevant yardstick is the sequential climb from $63.7 million and $1.78 per share last quarter, which would show whether the business is building toward the back-half weighting implied by full-year guidance of $270 million to $310 million in revenue.

The heart of the story is royalties. Royalty revenue grew 47%, 45% and 56% across the three quarters reported before the deal closed, and management guided 2026 royalty revenue to $225 million to $250 million. Because Zoma closed during the second quarter, this report should offer a cleaner read on what the acquired portfolio actually contributes. Investors should look for Filspari, now the largest royalty, to keep expanding following its FSGS approval, which arrived in April after a quarter's delay, and for steady progress from O2ver. Contributions from Vibismo, Roche's third best-selling product, and Ojemda, recently validated by Servier's $2.5 billion purchase of Day One, would help confirm that Zoma adds real recurring income rather than merely an attractive asset list.

That distinction matters because a good part of the deal's accretion math rests on tax attributes and synergies, including more than $110 million in Section 174 research credits, rather than pure organic growth. Management has talked about an extra $1.50 of 2027 EPS from Zoma and roughly $300 million of 2027 operating cash flow. Any update that reaffirms those targets, or quantifies milestone timing within the $2.3 billion of disclosed opportunities, would strengthen the narrative. Silence, or softer language ahead of December's Investor Day, would invite skepticism.

The pipeline adds another layer. Ligand has flagged as many as seven pivotal readouts over 18 months and has been candid that not all will succeed. The volixibat setback, where the FDA asked for a Phase 3 and pushed the PSC submission into the first half of 2027, is the cautionary example. Fresh delays elsewhere would chip at confidence, while clean timelines, plus progress toward a 2027 Vibismo filing in myopic CNV, would support it.

Sentiment has warmed, with the bearish reading easing to 16.2% from 23.3% a quarter ago, though it remains net negative. The stock has essentially tracked the market since the last report, but at $306.40 it trades well above its 200-day average of $247.78 and in the upper part of its post-earnings range, a few percent shy of the $317.49 high. The central question is whether third-quarter royalty growth and Zoma contributions are strong enough to make the $9 floor look conservative. If they are, consensus has room to rise; if not, the raised guidance will start to look borrowed from tax credits rather than earned.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.